{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:27:59Z","timestamp":1789504079087,"version":"build-2803163510"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>AbobotulinumtoxinA (aboBoNT-A) solution is a new ready-to-use formulation developed to reduce preparation time and improve reproducibility of injections.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To further evaluate treatment of moderate-to-severe glabellar lines (GLs) using pooled data from 2 Phase III studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>Following double-blind treatment with 50 U aboBoNT-A solution (n = 251) or placebo (n = 123), GL severity was assessed by investigators (ILA) and subjects (SSA). Other assessments included subject-reported time to onset, subject satisfaction, FACE-Q, and adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>One month after aboBoNT-A solution treatment, 88% had none-or-mild GLs at maximum frown and 93% had \u22651-grade improvement in ILA (similar for SSA), 24% to 27% remaining improved at Month 6. Glabellar lines responder rates remained higher than placebo throughout Month 6 (<jats:italic toggle=\"yes\">p<\/jats:italic> &lt; .001). Almost two-thirds of subjects reported onset within 3 days, nearly a quarter reporting effect by Day 1. Subject satisfaction with GL appearance, and FACE-Q satisfaction with facial appearance overall and psychological well-being were also improved over placebo throughout Month 6, <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; .05. Treatment-related adverse events were nonserious and mild or moderate.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Pooled analysis confirmed a duration of effect on GLs of up to 6 months for aboBoNT-A solution, with onset starting within 24 hours, high subject satisfaction, and improved psychological well-being. The treatment was well tolerated.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000003594","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T15:00:09Z","timestamp":1665154809000},"page":"1198-1202","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Liquid AbobotulinumtoxinA: Pooled Data From Two Double-Blind, Randomized, Placebo-Controlled Phase III Studies of Glabellar Line Treatment"],"prefix":"10.1097","volume":"48","author":[{"given":"Said","family":"Hilton","sequence":"first","affiliation":[{"name":"Dr. Hilton and Partner, D\u00fcsseldorf, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Kestemont","sequence":"additional","affiliation":[{"name":"159 Rimiez Esthetique, Nice, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Sattler","sequence":"additional","affiliation":[{"name":"Rosenpark Research, Darmstadt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Volteau","sequence":"additional","affiliation":[{"name":"Ipsen Innovation, Les Ulis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thompson","sequence":"additional","affiliation":[{"name":"Ipsen Innovation, Les Ulis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill","family":"Andriopoulos","sequence":"additional","affiliation":[{"name":"Galderma Laboratories LP, Fort Worth, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Prygova","sequence":"additional","affiliation":[{"name":"Galderma Aesthetics, Uppsala, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Karin","family":"Berg","sequence":"additional","affiliation":[{"name":"Galderma Aesthetics, Uppsala, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ascher","sequence":"additional","affiliation":[{"name":"Clinique I\u00e9na, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"R1-20250731","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/DSS.0000000000002013","article-title":"Efficacy, safety, and subject satisfaction after AbobotulinumtoxinA treatment for moderate to severe glabellar lines","volume":"46","author":"Monheit","year":"2020","journal-title":"Dermatol Surg"},{"key":"R2-20250731","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1093\/asj\/sjx010","article-title":"Safety and patient satisfaction of AbobotulinumtoxinA for aesthetic use: a systematic review","volume":"37","author":"Cohen","year":"2017","journal-title":"Aesthet Surg J"},{"issue":"Suppl 1","key":"R3-20250731","first-page":"1","volume":"24","author":"Rzany","year":"2010","journal-title":"Treatment of glabellar lines with botulinum toxin type A (Speywood Unit): a clinical overview. J Eur Acad Dermatol Venereol"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/DSS.0000000000002846","article-title":"A multicenter study to evaluate subject satisfaction with two treatments of AbobotulinumtoxinA a year in the glabellar lines","volume":"47","author":"Schlessinger","year":"2021","journal-title":"Dermatol Surg"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/asj\/sjw272","article-title":"Liquid formulation of AbobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial","volume":"38","author":"Ascher","year":"2018","journal-title":"Aesthet Surg J"},{"key":"R6-20250731","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/asj\/sjz003","article-title":"Liquid formulation of AbobotulinumtoxinA: a 6-month, Phase 3, double-blind, randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines","volume":"40","author":"Ascher","year":"2020","journal-title":"Aesthet Surg J"},{"key":"R7-20250731","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/asj\/sjab329","article-title":"Long-term efficacy and safety of liquid AbobotulinumtoxinA formulation for moderate-to-severe glabellar lines: a Phase III, double-blind, randomized, placebo-controlled and open-label study","volume":"42","author":"Kestemont","year":"2022","journal-title":"Aesthet Surg J"},{"key":"R8-20250731","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1046\/j.1365-2133.2003.05436.x","article-title":"Reproducibility of a four-point clinical severity score for glabellar frown lines","volume":"149","author":"Honeck","year":"2003","journal-title":"Br J Dermatol"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cps.2012.12.001","article-title":"Development and psychometric evaluation of the FACE-Q satisfaction with appearance scale: a new patient-reported outcome instrument for facial aesthetics patients","volume":"40","author":"Pusic","year":"2013","journal-title":"Clin Plast Surg"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/PRS.0000000000000895","article-title":"FACE-Q scales for health-related quality of life, early life impact, satisfaction with outcomes, and decision to have treatment: development and validation","volume":"135","author":"Klassen","year":"2015","journal-title":"Plast Reconstr Surg"},{"key":"R11-20250731","doi-asserted-by":"crossref","first-page":"980","DOI":"10.36849\/JDD.6263","article-title":"AbobotulinumtoxinA for the treatment of moderate-to-severe glabellar lines: a randomized, dose-escalating, double-blind study","volume":"20","author":"Joseph","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"R12-20250731","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1111\/j.1524-4725.2009.01235.x","article-title":"Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety","volume":"35","author":"Brandt","year":"2009","journal-title":"Dermatol Surg"},{"key":"R13-20250731","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/archfaci.2009.5","article-title":"Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines","volume":"11","author":"Moy","year":"2009","journal-title":"Arch Facial Plast Surg"},{"key":"R14-20250731","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1007\/s00266-018-1200-4","article-title":"Assessment of subject and physician satisfaction after long-term treatment of glabellar lines with AbobotulinumtoxinA (Dysport((R))\/Azzalure((R))): primary results of the APPEAL noninterventional study","volume":"42","author":"Gubanova","year":"2018","journal-title":"Aesthet Plast Surg"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000003594","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:09:13Z","timestamp":1753999753000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000003594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000003594","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]}}}